Displaying drugs 751 - 775 of 11014 in total
Ziprasidone
Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior. These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. Luckily, several treatment options for psychotic disorders have been...
Approved
Matched Description: … treat manic episodes in bipolar disorder although the mechanism of action is unknown. ... [A180748] It can effectively reduce the rate and time of relapses in schizophrenia, and can be used to ... life of patients and caregivers. …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Idarucizumab
Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its anticoagulant effect. As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when...
Approved
Matched Description: … dabigatran-associated bleeding in life-threatening or surgically induced situations. ... As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran ... Its use is associated with immediate, complete and sustained reversal of the anticoagulant effects of …
Trolamine salicylate
Trolamine salicylate is an organic compound or a salt formed between triethanolamine and salicylic acid. Triethanolamine neutralizes the acidity of the salicylic acid. It is a topical analgesic used for temporary relief of minor pain associated with arthritis, simple backache, muscle strains, sprains, and bruises. Unlike other topical analgesics, trolamine...
Approved
Matched Description: … Trolamine salicylate serves as an active ingredient in topical over-the-counter products for temporary ... Triethanolamine neutralizes the acidity of the salicylic acid. ... management of mild to moderate muscular and joint pains. …
Calcium glubionate anhydrous
Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets.
Approved
Matched Description: … glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in …
Hydroxyzine
Hydroxyzine is a first-generation histamine H1-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. The active metabolite of hydroxyzine,...
Approved
Matched Description: … in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. ... [A1257,A187589] It was first developed in 1955,[A189726] and has since remained a relatively common treatment ... Hydroxyzine is a first-generation histamine H1-receptor antagonist of the dephenylmethane …
Meperidine
A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.
Approved
Matched Description: … A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including ... postoperative pain and the pain of labor. ... with morphine and are of shorter duration. …
Matched Salts cas: … 50-13-5 …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Matched Salts cas: … 50-13-5 …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Miltefosine
Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of leishmaniasis, a neglected tropical disease. It can be administered topically or orally and...
Approved
Investigational
Matched Description: … It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of ... is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in ... It can be administered topically or orally and is only indicated in patients aged 12 years or older. …
Loxoprofen
Loxoprofen is a propionic acid derivative non-steroidal anti-inflammatory drug. It is marketed under the trade name Loxonin in Brazil, Mexico and Japan by Sankyo, as Loxomac in India, and as Oxeno in Argentina. A transdermal preparation was approved for use in Japan in January 2006.
Approved
Matched Description: … A transdermal preparation was approved for use in Japan in January 2006. ... , and as Oxeno in Argentina. ... It is marketed under the trade name Loxonin in Brazil, Mexico and Japan by Sankyo, as Loxomac in India …
Potassium bicarbonate
Potassium bicarbonate is a white, crystalline, slightly alkaline and salty substance. It is produced by the passage of carbon dioxide through an aqueous potassium carbonate solution. It is used in medicine as an antacid. It is registered in the FDA under the section of suitable, safe and effective ingredients for...
Approved
Matched Description: … [T141] It is registered in the FDA under the section of suitable, safe and effective ingredients for ... It is used in medicine as an antacid. ... It is produced by the passage of carbon dioxide through an aqueous potassium carbonate solution. …
Tildrakizumab
Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis .
The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy...
Approved
Investigational
Matched Description: … the evolution of treatment strategy in chronic plaque psoriasis [A32255]. ... The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects [A32257 ... The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every …
Cenegermin
Cenegermin is a human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli. It received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. Neurotrophic keratitis is a...
Approved
Investigational
Matched Description: … Cenegermin received approval from the US FDA a year later in August of 2018. ... It received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic ... The prevalence of neurotrophic keratitis has been estimated to be less than five in 10,000 individuals …
Phentermine
Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows this agent to...
Approved
Illicit
Matched Description: … ] was discontinued after finding several reports of abnormal valves in nearly 30% of the consumers. ... Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity ... used in 1960. …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Benzphetamine
A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)
Approved
Illicit
Matched Description: … It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Ergotamine
A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders.
Approved
Matched Iupac: … (4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}] …
Matched Description: … A vasoconstrictor found in ergot of Central Europe. ... It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Matched Description: … A vasoconstrictor found in ergot of Central Europe. ... It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Cyclobenzaprine
Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from Amitriptyline by only a single double bond.[A185039,A184982] Since its approval, it has...
Approved
Matched Description: … Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961[A185039] and has been …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Pizotifen
Pizotifen belongs to the class of antamines and is related to cyproheptadine. It is a potent serotonin and tryptamine antagonist that has been used for migraine prevention for many years. It exhibits weak anticholinergic, antihistamine, and antikinin actions in addition to sedative and appetite-stimulating properties . Some patients receiving pizotifen...
Approved
Matched Iupac: … 1-methyl-4-{6-thiatricyclo[8.4.0.0³,⁷]tetradeca-1(14),3(7),4,10,12-pentaen-2-ylidene}piperidine …
Matched Description: … Sandomigran is available in a number of countries but is not approved by the FDA nor EMA. ... of migraines. ... Pizotifen hydrochloride is an active ingredient in Sandomigran, which is used for the prophylactic management …
Matched Salts cas: … 5189-11-7 …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Matched Description: … Sandomigran is available in a number of countries but is not approved by the FDA nor EMA. ... of migraines. ... Pizotifen hydrochloride is an active ingredient in Sandomigran, which is used for the prophylactic management …
Matched Salts cas: … 5189-11-7 …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Mirabegron
Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is...
Approved
Matched Description: … the bladder in the treatment of urinary frequency and incontinence. ... of adults with overactive bladder. ... these medications and their broad range of adverse effects. …
LetibotulinumtoxinA
The aesthetic utility of botulinum toxin was discovered incidentally following its initial use in the treatment of facial spasmodic disorders in the early 1970s. The first aesthetic use of botulinum toxin was reported in 1989, when onabotulinumtoxinA (Botox) was used as a treatment for facial asymmetry resulting from iatrogenic facial...
Approved
Matched Description: … treatment of facial spasmodic disorders in the early 1970s. ... [L42335] It was approved for use in the treatment of glabellar lines in Canada in June 2022[L42330,L42335 ... The aesthetic utility of botulinum toxin was discovered incidentally following its initial use in the …
Glycerol phenylbutyrate
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Approved
Matched Description: … Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol …
Regorafenib
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Approved
Matched Description: … Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017. ... Regorafenib is an orally-administered inhibitor of multiple kinases. ... It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours …
Drotaverine
Drotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4 (PDE4). It is a benzylisoquinoline derivative that is structurally related to papaverine, although it displays more potent antispasmodic activities than papaverine. Drotaverine has been used in the symptomatic treatment of various spastic conditions, such as gastrointestinal diseases, biliary dyskinesia, and...
Approved
Investigational
Matched Description: … [A7036] It also has been investigated in dysmenorrhea, abortion, [A231609] and augmentation of labour ... [A231614] More recently, drotaverine gained attention in the treatment of benign prostatic hyperplasia ... Drotaverine has been used in the symptomatic treatment of various spastic conditions, such as gastrointestinal …
Elbasvir
Elbasvir is a direct-acting antiviral medication used as part of combination therapy to treat chronic hepatitis C, an infectious liver disease caused by infection with hepatitis C virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in...
Approved
Matched Iupac: … pyrrolidin-2-yl]-1H-imidazol-5-yl}-9-phenyl-8-oxa-10-azatetracyclo[8.7.0.0^{2,7}.0^{11,16}]heptadeca-1(17),2(7) …
Matched Description: … Approved in January 2016 by the FDA, Zepatier is indicated for the treatment of HCV genotypes 1 and 4 ... [A19626] In a computational target-based drug repurposing investigation published in April 2020, elbasvir ... single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in …
Matched Categories: … Antivirals for treatment of HCV infections …
Matched Description: … Approved in January 2016 by the FDA, Zepatier is indicated for the treatment of HCV genotypes 1 and 4 ... [A19626] In a computational target-based drug repurposing investigation published in April 2020, elbasvir ... single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in …
Matched Categories: … Antivirals for treatment of HCV infections …
Bulevirtide
Hepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development of cirrhosis, severe decompensation of liver function, and an increased risk of mortality.[A226340,L30235] Until recently, there have been extremely limited treatments available for Hepatitis D infection. Bulevirtide, also known as Hepcludex, is a...
Approved
Investigational
Matched Description: … Completion of this clinical trial is anticipated in early 2023.[L30240] ... is also under investigation in clinical trial NCT03852433 (Phase 2b Study of Bulevirtide With [Peginterferon ... of cirrhosis, severe decompensation of liver function, and an increased risk of mortality. …
Aclidinium
Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
Approved
Matched Description: … Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease …
Florbetapir (18F)
Florbetapir (18F) is a radiopharmaceutical compound containing the radionuclide fluorine-18 bound to the compound florbetapir, a molecule that binds with high affinity to beta amyloid plaque, a peptide that plays a key role in Alzheimer's Disease pathogenesis. Marketed as the product Amyvid, florbetapir 18F is indicated for positron emission tomography...
Approved
Investigational
Matched Description: … sufficiently in the brain before undergoing positon emission decay. ... who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. ... as the product Amyvid, florbetapir 18F is indicated for positron emission tomography (PET) imaging of …
Displaying drugs 751 - 775 of 11014 in total